Thrombomodulin Alfa

Summary

Thrombomodulin Alfa (CHEMBL2108653) is a phase-3 clinical-stage unknown; indicated across 3 conditions including idiopathic pulmonary fibrosis and colonic neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108653
Name	Thrombomodulin Alfa
Type	Unknown
Max phase	3

Also known as: ART-123, Recomodulin, Recomodulin (japan only), Thrombomodulin alfa, Thrombomoduline alfa, Trombomodulina alfa, THROMBOMODULIN ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
idiopathic pulmonary fibrosis	3	MONDO:0800504	EFO:0000768
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
peripheral neuropathy	2	MONDO:0005244	EFO:0003100

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	3
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01704001	PHASE4	COMPLETED	Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment
NCT01598831	PHASE3	COMPLETED	Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
NCT02739165	PHASE3	COMPLETED	Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT03517501	PHASE3	WITHDRAWN	The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
NCT00487656	PHASE2	COMPLETED	Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
NCT02792842	PHASE2	COMPLETED	Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
NCT04492436	PHASE2	WITHDRAWN	A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
NCT05251727	PHASE1	TERMINATED	Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).